Highlights

  • Neuren shares decline 31.11% over the past month despite recent recovery in short-term trading.
  • Company plans on-market buy-back not exceeding 5% of total shares, contingent on market conditions.
  • Buy-back aims to reduce shares on issue while ongoing NNZ-2591 development programs remain funded.

Neuren Pharmaceuticals Ltd. (ASX:NEU) has experienced notable fluctuations in its share performance, reflecting market volatility and investor focus on the company’s ongoing operations and strategic initiatives. The stock has seen periods of both short-term recovery and longer-term adjustments, drawing attention to market sentiment and trading trends.

Share Performance Snapshot
Neuren Pharmaceuticals shares closed at 13.31 AUD on 12 February 2026, down 1.48% on the day. Over the past five days, NEU gained 1.68%, though the stock has faced a broader decline of 31.11% over the past month.

Six-month and year-to-date metrics also show decreases 25.56% and 29.61% respectively. Longer-term trends reflect growth, with a 1-year increase of 1.99%, a 5-year gain of 830.77%, and an all-time increase of 122.95%.

The stock’s volatility reflects mixed investor sentiment, impacted by both operational updates and broader market conditions. NEU has experienced fluctuations in daily trading despite maintaining regulatory approvals and ongoing development programs.

Broker Consensus Signals
According to EODHD/Others data as of 12 Feb 2026, Analysts maintain a positive outlook on Neuren Pharmaceuticals Ltd., assigning a BUY rating. The consensus target price stands at AUD 23.45, implying a potential upside of approximately 76.6% from current levels.

Expectations are supported by Neuren’s ongoing pharmaceutical developments, strategic positioning in neurology treatments, and promising growth prospects in the biotech sector, even as broader healthcare markets face regulatory and clinical trial uncertainties.

On-Market Share Buy-Back Program
On 11 February 2026, Neuren announced a new on-market share buyback program, permitted under section 65 of the New Zealand Companies Act 1993. The buy-back will not exceed 5% of total shares issued 12 months prior to the commencement of the program and will be executed at the company’s discretion.

During the buy-back period, lasting up to 12 months, Neuren will assess factors including market conditions, prevailing share prices, operational performance, and investment opportunities. The company may suspend, vary, or terminate the buy-back at any point. Shares purchased will be cancelled upon acquisition, reducing the total number of shares on issue.

The buy-back will exclude designated blackout periods, such as the release of annual financial results. For 2025, Neuren’s Appendix 4E Preliminary final report is scheduled for 27 February 2026. The number of shares bought and the average price will be disclosed on the ASX after each purchase.

Ongoing Development Programs
Neuren continues to advance its NNZ-2591 development programs targeting Phelan-McDermid syndrome, Pitt Hopkins syndrome, and HIE. These programs, along with the DAYBUE® franchise, remain funded alongside the buy-back initiative. DAYBUE® (trofinetide) and DAYBUE STIX are FDA-approved treatments for Rett syndrome, with commercial rights licensed to Acadia Pharmaceuticals Inc.

NNZ-2591 has orphan drug designation in both the US and EU, supporting ongoing clinical trials, including Phase 3 in Phelan-McDermid syndrome and positive Phase 2 results in Pitt Hopkins and Angelman syndromes.

Neuren’s recent announcement of an on-market buy-back reflects ongoing measures to manage share supply amid volatile performance, while NNZ-2591 and DAYBUE® development programs continue to be funded. The stock’s fluctuations over the past month and six months highlight investor focus on both operational execution and broader market dynamics.

FAQs
Q1. What is the scope of Neuren’s buy-back program?
The buy-back will not exceed 5% of total shares issued 12 months prior and will be executed at the company’s discretion.

Q2. How is Neuren’s share performance trending?
Shares declined 31.11% over the past month, down 5.60 AUD (29.61%) year-to-date, with mixed performance over longer periods.

Q3. What are the key ongoing development programs?
Neuren is advancing NNZ-2591 clinical trials in multiple neurodevelopmental disorders and maintains the FDA-approved DAYBUE® franchise.